{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:43:56Z","timestamp":1785545036826,"version":"3.56.0"},"reference-count":76,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec sec-type=\"background\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Erythema nodosum leprosum (ENL) is an immunological complication affecting up to 10% of borderline lepromatous and 50% of lepromatous leprosy cases with a high bacterial index (3\u20106+). Current treatments often require prolonged therapy over years and cause significant long-term side effects, highlighting the need for new therapies. Therefore, it is imperative to identify new therapies for ENL. Phosphodiesterase 4 inhibitors are a class of compounds that mediate immune homeostasis and have the potential to treat ENL with fewer side effects. Dovramilast (formerly CC-11050) is an anti-inflammatory phosphodiesterase 4 inhibitor; to date, it has been shown to be well tolerated in phase 1 human studies. This is the first phase 2 study of dovramilast in ENL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"objective\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This phase 2 pilot study aims to assess the safety and tolerability of dovramilast and to explore preliminary clinical responses in patients with new or recurrent ENL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was designed in two steps: (1) 28 days of treatment for 10 males to ensure safety and (2) an initial 12-week treatment course, with the option to retreat if further ENL episodes occur (up to 48 wk of treatment), for up to 40 males or females, as required on a case-by-case basis. Demographic, clinical, and laboratory data will be collected longitudinally, along with the ENL International Study Group ENL Severity Scale, Brief Pain Inventory, and Douleur Neuropathique 4 questionnaire for the identification of neuropathic pain. Patients will be followed for 12 months for ENL recurrence after cessation of the study drug. Safety will be evaluated through adverse event reporting and laboratory monitoring, while efficacy will be assessed using descriptive and trend-based analyses of changes in ENL severity, pain, and clinical outcomes over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The initial safety evaluation (step 1) of this phase 2 pilot study was completed and reviewed by an independent Data Safety Monitoring Board, which did not identify safety concerns that would preclude continuation of the study. Based on the step 1 results, the study proceeded to step 2, which evaluates longer-term administration of dovramilast in male and female participants. As of April 2026, a total of 15 participants have been recruited. All study data are anticipated to be collected by September 2027, with publication of the main trial results expected by December 2027.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This phase 2 pilot study is designed to generate preliminary data on the safety, tolerability, and potential clinical signals of dovramilast in patients with new or recurrent ENL. Findings from this exploratory trial will inform the feasibility, outcome measures, and design of future adequately powered randomized controlled studies and do not directly support changes to current clinical practice at this stage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2196\/88069","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T20:56:42Z","timestamp":1781729802000},"page":"e88069-e88069","source":"Crossref","is-referenced-by-count":0,"title":["Dovramilast for Erythema Nodosum Leprosum in Patients With Leprosy in Nepal: Protocol for a Phase 2 Open-Label Pilot Study"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5628-7851","authenticated-orcid":false,"given":"Mahesh","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5709-5958","authenticated-orcid":false,"given":"Divya RSJB","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2553-5937","authenticated-orcid":false,"given":"Kapil Dev","family":"Neupane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4705-8480","authenticated-orcid":false,"given":"Preeti","family":"Maharjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5730-418X","authenticated-orcid":false,"given":"Suwash","family":"Baral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1643-8806","authenticated-orcid":false,"given":"Reejana","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9469-2148","authenticated-orcid":false,"given":"Jivan","family":"Shakya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-1212","authenticated-orcid":false,"given":"Binod","family":"Aryal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-0574","authenticated-orcid":false,"given":"Bishwanath","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-880X","authenticated-orcid":false,"given":"Indra Bahadur","family":"Napit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3792-2266","authenticated-orcid":false,"given":"Deanna A","family":"Hagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"R1","unstructured":"Global leprosy (Hansen disease)\u200e update, 2023: elimination of leprosy disease is possible \u2013 time to act! [Report in French]. World Health Organization; 2024. URL: https:\/\/iris.who.int\/bitstream\/handle\/10665\/378895\/WER9937-501-521.pdf?sequence=1 [Accessed 20-08-2025]"},{"key":"R2","unstructured":"The global health observatory: leprosy (Hansen\u2019s disease). World Health Organization. URL: https:\/\/www.who.int\/data\/gho\/data\/themes\/topics\/leprosy-hansens-disease [Accessed 20-08-2025]"},{"issue":"8","key":"R3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1365-4632.2011.05414.x","article-title":"The leprosy agents  and  in Mexico","volume":"51","author":"Han","journal-title":"Int J Dermatol"},{"key":"R4","unstructured":"FAQs: frequently asked questions on leprosy. World Health Organization; 2013. URL: https:\/\/iris.who.int\/bitstream\/handle\/10665\/205085\/B5044.pdf?sequence=1 [Accessed 20-11-2024]"},{"key":"R5","unstructured":"Guidelines for the diagnosis, treatment and prevention of leprosy. World Health Organization; 2018. URL: https:\/\/www.who.int\/publications\/i\/item\/9789290226383 [Accessed 18-11-2024]"},{"issue":"5","key":"R6","doi-asserted-by":"crossref","first-page":"868","DOI":"10.4269\/ajtmh.2006.74.868","volume":"74","author":"Pocaterra","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"R7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5935\/0305-7518.19940019","article-title":"Reactions in leprosy: an epidemiological study of 386 patients in West Nepal","volume":"65","author":"Van Brakel","journal-title":"Lepr Rev"},{"issue":"3","key":"R8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.47276\/lr.79.3.254","volume":"79","author":"Feuth","journal-title":"Lepr Rev"},{"issue":"3","key":"R9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002089","article-title":"Diagnosis and treatment of leprosy reactions in integrated services--the patients\u2019 perspective in Nepal","volume":"7","author":"Raffe","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"R10","first-page":"189","volume":"60","author":"Rao","journal-title":"Indian J Lepr"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.5935\/0305-7518.20000033","article-title":"The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome","volume":"71","author":"Saunderson","journal-title":"Lepr Rev"},{"issue":"7","key":"R12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006610","article-title":"Diagnosis and impact of neuropathic pain in leprosy patients in Nepal after completion of multidrug therapy","volume":"12","author":"Toh","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"R13","doi-asserted-by":"publisher","first-page":"637","DOI":"10.4269\/ajtmh.2010.09-0586","article-title":"Reactions following completion of 1 and 2 year multidrug therapy (MDT)","volume":"83","author":"Balagon","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"R14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.trstmh.2008.01.004","article-title":"Towards understanding the pathology of erythema nodosum leprosum","volume":"102","author":"Kahawita","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"1","key":"R15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4269\/ajtmh.13-0221","article-title":"Risk factors for leprosy reactions in three endemic countries","volume":"92","author":"Scollard","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"R16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002440","article-title":"A systematic review on the epidemiological data of erythema nodosum leprosum, a type 2 leprosy reaction","volume":"7","author":"Voorend","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"R17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1046\/j.1365-2133.2001.03970.x","article-title":"Sequential erythema nodosum leprosum and reversal reaction with similar lesional cytokine mRNA patterns in a borderline leprosy patient","volume":"144","author":"Moraes","journal-title":"Br J Dermatol"},{"issue":"3","key":"R18","first-page":"316","volume":"66","author":"Rea","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"9","key":"R19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004065","article-title":"ENLIST 1: an international multi-centre cross-sectional study of the clinical features of erythema nodosum leprosum","volume":"9","author":"Walker","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"R20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1440-0960.2009.00534.x","article-title":"Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study","volume":"50","author":"Kaur","journal-title":"Australas J Dermatol"},{"issue":"4","key":"R21","first-page":"497","volume":"51","author":"Ramu","journal-title":"Lepr India"},{"issue":"2","key":"R22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.47276\/lr.78.2.161","volume":"78","author":"Van Brakel","journal-title":"Lepr Rev"},{"issue":"3","key":"R23","first-page":"270","volume":"67","author":"Manandhar","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"7","key":"R24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005716","article-title":"A leprosy clinical severity scale for erythema nodosum leprosum: an international, multicentre validation study of the ENLIST ENL Severity Scale","volume":"11","author":"Walker","journal-title":"PLoS Negl Trop Dis"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0385-2018","article-title":"Adverse events in patients with leprosy on treatment with thalidomide","volume":"52","author":"Drummond","journal-title":"Rev Soc Bras Med Trop"},{"key":"R26","unstructured":"List of laboratory tests to be performed during the trial. asterisk (*) indicates the subset of tests performed in step 1. All tests will be performed in the step 2. bioRENDER. URL: https:\/\/BioRender.com\/k49w070 [Accessed 26-05-2026]"},{"issue":"1","key":"R27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003431","article-title":"Household costs of leprosy reactions (ENL) in rural India","volume":"9","author":"Chandler","journal-title":"PLoS Negl Trop Dis"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/j.actatropica.2018.02.026","article-title":"Erythema nodosum leprosum: update and challenges on the treatment of a neglected condition","volume":"183","author":"Costa","journal-title":"Acta Trop"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01149","article-title":"New insight into the pathogenesis of erythema nodosum leprosum: the role of activated memory T-cells","volume":"8","author":"Negera","journal-title":"Front Immunol"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00233","article-title":"A systematic review of immunological studies of erythema nodosum leprosum","volume":"8","author":"Polycarpou","journal-title":"Front Immunol"},{"issue":"4","key":"R31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.4103\/idoj.IDOJ_69_20","article-title":"Current concepts and challenges in the management of erythema nodosum leprosum","volume":"11","author":"Singal","journal-title":"Indian Dermatol Online J"},{"issue":"5","key":"R32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1046\/j.1365-3083.1999.00622.x","article-title":"Cytokine mRNA expression in leprosy: a possible role for interferon-gamma and interleukin-12 in reactions (RR and ENL)","volume":"50","author":"Moraes","journal-title":"Scand J Immunol"},{"issue":"9","key":"R33","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/infdis\/jis208","article-title":"Genetic and immunological evidence implicates interleukin 6 as a susceptibility gene for leprosy type 2 reaction","volume":"205","author":"Sousa","journal-title":"J Infect Dis"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.08.026","article-title":"Opening a can of worms: leprosy reactions and complicit soil-transmitted helminths","volume":"23","author":"Hagge","journal-title":"EBioMedicine"},{"issue":"3","key":"R35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006949.pub2","article-title":"Interventions for erythema nodosum leprosum","volume":"2009","author":"Van Veen","journal-title":"Cochrane Database Syst Rev"},{"key":"R36","unstructured":"Leprosy\/Hansen disease: management of reactions and prevention of disabilities. World Health Organization; 2020. URL: https:\/\/www.who.int\/publications\/i\/item\/9789290227595 [Accessed 18-11-2025]"},{"issue":"3","key":"R37","doi-asserted-by":"publisher","first-page":"236","DOI":"10.47276\/lr.92.3.236","article-title":"Prednisolone adverse events in the treatment and prevention of leprosy neuropathy in two large double blind randomized clinical trials","volume":"92","author":"Post","journal-title":"Lepr Rev"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1177\/20503121221089448","article-title":"Analysis of therapeutic effectiveness and adverse effects of long-term corticosteroids among leprosy patients with reactions: a retrospective cohort study","volume":"10","author":"Siagian","journal-title":"SAGE Open Med"},{"issue":"1","key":"R39","first-page":"10","volume":"66","author":"Sugumaran","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reactions","volume":"6","author":"Sheskin","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"R41","doi-asserted-by":"publisher","first-page":"208","DOI":"10.47276\/lr.88.2.208","article-title":"A prospective randomised, double-blind, placebo controlled trial on the effect of extended clofazimine on erythema nodosum leprosum (ENL) in multibacillary (MB) leprosy","volume":"88","author":"Maghanoy","journal-title":"Lepr Rev"},{"issue":"5","key":"R42","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1093\/cid\/ciq213","article-title":"Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept","volume":"52","author":"Ramien","journal-title":"Clin Infect Dis"},{"issue":"2","key":"R43","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ijmyco.2016.02.002","article-title":"Treatment of severe refractory erythema nodosum leprosum with tumor necrosis factor inhibitor Etanercept","volume":"5","author":"Chowdhry","journal-title":"Int J Mycobacteriol"},{"issue":"6","key":"R44","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.4269\/ajtmh.16-0118","article-title":"Therapeutic dilemma of refractory erythema nodosum leprosum","volume":"96","author":"Zhu","journal-title":"Am J Trop Med Hyg"},{"issue":"11","key":"R45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037700","article-title":"Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial","volume":"10","author":"de Barros","journal-title":"BMJ Open"},{"issue":"4","key":"R46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0011238","article-title":"Methotrexate as a corticosteroid-sparing agent in leprosy reactions: a French multicenter retrospective study","volume":"17","author":"Jaume","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"R47","first-page":"441","volume":"55","author":"Miller","journal-title":"Int J Lepr Other Mycobact Dis"},{"issue":"2","key":"R48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004149","article-title":"Comparison of efficacy and safety of ciclosporin to prednisolone in the treatment of erythema nodosum leprosum: two randomised, double blind, controlled pilot studies in Ethiopia","volume":"10","author":"Lambert","journal-title":"PLoS Negl Trop Dis"},{"key":"R49","unstructured":"Tapia C Nessel TA Zito PM . Cyclosporine. In: StatPearls. StatPearls Publishing; 2025. [Medline: 29494057]"},{"issue":"10","key":"R50","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.trstmh.2003.12.013","article-title":"Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal","volume":"98","author":"Marlowe","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"3","key":"R51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005348","article-title":"AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and type 1 reactions in India: main findings","volume":"11","author":"Lockwood","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"R52","doi-asserted-by":"crossref","first-page":"304","DOI":"10.47276\/lr.82.3.304","volume":"82","author":"Dur\u00e3es","journal-title":"Lepr Rev"},{"issue":"8","key":"R53","doi-asserted-by":"publisher","first-page":"FD01","DOI":"10.7860\/JCDR\/2017\/26536.10499","article-title":"Azathioprine in chronic recalcitrant erythema nodosum leprosum: a case report","volume":"11","author":"Jitendra","journal-title":"J Clin Diagn Res"},{"key":"R54","unstructured":"Mohammadi O Kassim TA . Azathioprine. In: StatPearls. StatPearls Publishing; 2025. [Medline: 31194347]"},{"issue":"3","key":"R55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"R56","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.4269\/ajtmh.19-0616","article-title":"Biologics in leprosy: a systematic review and case report","volume":"102","author":"Cogen","journal-title":"Am J Trop Med Hyg"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.879527","article-title":"Case report: a case series of immunobiological therapy (anti-TNF-\u03b1) for patients with erythema nodosum leprosum","volume":"9","author":"Mendes","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"R58","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1396-0296.2004.04044.x","article-title":"Infliximab","volume":"17","author":"Winterfield","journal-title":"Dermatol Ther"},{"issue":"2 Suppl","key":"R59","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/mjd.2003.554","article-title":"Etanercept: an overview","volume":"49","author":"Goffe","journal-title":"J Am Acad Dermatol"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00238","article-title":"Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of","volume":"7","author":"Subbian","journal-title":"Front Immunol"},{"key":"R61","unstructured":"Amgen is supporting advancement of AMG 634 for global health diseases in developing countries. Amgen. URL: https:\/\/www.amgen.com\/newsroom\/press-releases\/2020\/06\/amgen-is-supporting-advancement-of-amg-634-for-global-health-diseases-in-developing-countries [Accessed 23-05-2026]"},{"key":"R62","unstructured":"Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion. Reuters. URL: https:\/\/www.reuters.com\/article\/business\/amgen-to-buy-celgene-psoriasis-drug-otezla-for-134-billion-idUSKCN1VG102\/ [Accessed 18-11-2024]"},{"key":"R63","unstructured":"MDGH acquires a new potential treatment of tuberculosis and leprosy. Medicines Development for Global Health (MDGH). URL: https:\/\/www.medicinesdevelopment.com\/news\/mdgh-update-march-2021 [Accessed 18-11-2024]"},{"issue":"6","key":"R64","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz246","article-title":"A phase I, randomized, controlled clinical study of CC-11050 in people living with HIV with suppressed plasma viremia on antiretroviral therapy (APHRODITE)","volume":"6","author":"Boulougoura","journal-title":"Open Forum Infect Dis"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2016.01.015","article-title":"Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model","volume":"4","author":"Subbian","journal-title":"EBioMedicine"},{"key":"R66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1270414","article-title":"A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection","volume":"14","author":"Kolloli","journal-title":"Front Immunol"},{"issue":"8","key":"R67","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","journal-title":"Lancet Respir Med"},{"issue":"5","key":"R68","doi-asserted-by":"crossref","first-page":"518","DOI":"10.4269\/ajtmh.2005.72.518","volume":"72","author":"Villahermosa","journal-title":"Am J Trop Med Hyg"},{"issue":"12","key":"R69","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1086\/498216","article-title":"Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation","volume":"192","author":"Haslett","journal-title":"J Infect Dis"},{"issue":"3","key":"R70","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","journal-title":"Ann Intern Med"},{"key":"R71","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institute; 2017. URL: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf [Accessed 05-04-2026]"},{"key":"R72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","journal-title":"Front Pharmacol"},{"issue":"9843","key":"R73","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","journal-title":"Lancet"},{"issue":"4","key":"R74","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/bjd.18233","article-title":"Apremilast in chronic recalcitrant erythema nodosum leprosum: a report of two cases","volume":"182","author":"Narang","journal-title":"Br J Dermatol"},{"issue":"12","key":"R75","doi-asserted-by":"publisher","first-page":"e917","DOI":"10.1111\/jdv.17585","article-title":"Apremilast in multibacillary leprosy patients with chronic and recurrent erythema nodosum leprosum: a prospective single-centre pilot study","volume":"35","author":"Narang","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"R76","doi-asserted-by":"publisher","first-page":"42","DOI":"10.4103\/jdds.jdds_45_23","article-title":"Apremilast in erythema nodosum leprosum: a case series","volume":"28","author":"Mandloi","journal-title":"J Dermatol Dermatol Surg"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e88069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:25:01Z","timestamp":1785536701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e88069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":76,"URL":"https:\/\/doi.org\/10.2196\/88069","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"v15i8e88069"}}